Dr. Scott Pollack – IDO Inhibitors and their Pharmacological Effects

In conjunction with his presentation at the London Excel at ELRIG Drug Discovery 2018, Dr. Scott Pollack, Associate Director of Biophysics and Enzymology at Sygnature Discovery, was asked:

“What are IDO inhibitors and how do you assess their pharmacological effects?”

Latest News

View All

Sygnature Discovery Receives EcoVadis Award For Sustainable…

Sygnature Discovery goes for global industry recognition…

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…